GoAI
Get started
Sipai Health Technology Co., Ltd. logo

Sipai Health Technology Co., Ltd.

0314.HK

HKSEHealthcareMedical - Distribution

Open in GoAI

Latest quote

HK$1.555

+HK$0.025 · +1.63%

Aug 24, 11:50 AM HKT

0314.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Sipai Health Technology Co., Ltd. is a Chinese enterprise specializing in medical technology and health management. Its business operations are diversified across three primary divisions: Specialty Pharmacy, Physician Research Assistance, and Health Insurance Services. The Specialty Pharmacy division manages a network of dedicated pharmacies and is also involved in the distribution of pharmaceutical products to drug manufacturers and other supply chain partners. Through its Physician Research Assistance segment, Sipai Health provides comprehensive site management organization (SMO) support to pharmaceutical firms and clinical research institutions. These services encompass a broad spectrum, including site identification and setup, patient acquisition and oversight, data and document handling, on-site logistical management of drugs and biosamples, and trial conclusion. Additionally, this segment offers specialized image management for clinical studies. The Health Insurance Services division functions as an intermediary, delivering brokerage solutions to various insurance providers. Established in 2014, the company's headquarters are situated in Guangzhou, China.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
CN
CEO
Xuguang Ma
Listed since
Dec 23, 2022
Employees
3,131

Market position

Day range

Current HK$1.555

52-week range

Current HK$1.555

Open
HK$1.53
Previous close
HK$1.53
Volume
321.8K
0.32× average
Average volume
1M
Average daily volume
Market cap
1.13B HKD
Beta
-0.58
Market reference 1
50-day average
HK$1.3606
+14.29% above average
200-day average
HK$1.9509
-20.29% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.06B CNY
P/E (TTM)
-11.35×
P/B (TTM)
0.87×
P/S (TTM)
0.79×
EV / EBITDA
-14.07×
Earnings yield
-8.99%
Free cash flow yield
0.01%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
14.39%
Operating margin
-5.15%
Net margin
-5.88%
Return on equity
-12.92%
Return on assets
-7.55%
Return on invested capital
-10.78%

Financial health

Debt / equity
0.02×
Current ratio
1.83×
Altman Z-score
-4.03
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends26%-23%-71%-120%Gross margin, FY2021: 8.09%Gross margin, FY2022: 8.19%Gross margin, FY2023: 8.80%Gross margin, FY2024: 8.46%Gross margin, FY2025: 13.73%Operating margin, FY2021: -21.48%Operating margin, FY2022: -15.37%Operating margin, FY2023: -6.02%Operating margin, FY2024: -6.12%Operating margin, FY2025: -5.04%Net margin, FY2021: -107.67%Net margin, FY2022: -33.27%Net margin, FY2023: -5.43%Net margin, FY2024: -7.09%Net margin, FY2025: -6.00%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 8.09%. Gross margin FY2022 8.19%. Gross margin FY2023 8.80%. Gross margin FY2024 8.46%. Gross margin FY2025 13.73%. Operating margin FY2021 -21.48%. Operating margin FY2022 -15.37%. Operating margin FY2023 -6.02%. Operating margin FY2024 -6.12%. Operating margin FY2025 -5.04%. Net margin FY2021 -107.67%. Net margin FY2022 -33.27%. Net margin FY2023 -5.43%. Net margin FY2024 -7.09%. Net margin FY2025 -6.00%.

Income trends

Revenue

2.02B CNY-55.81%

Operating income

−101.71M CNY+63.62%

Net income

−121.05M CNY+62.61%
Income trends across reported periods5.56B CNY2.18B CNY−1.2B CNY−4.59B CNYRevenue, FY2021: 3.47B CNYRevenue, FY2022: 4.12B CNYRevenue, FY2023: 4.71B CNYRevenue, FY2024: 4.57B CNYRevenue, FY2025: 2.02B CNYOperating income, FY2021: −746.04M CNYOperating income, FY2022: −633.13M CNYOperating income, FY2023: −283.57M CNYOperating income, FY2024: −279.59M CNYOperating income, FY2025: −101.71M CNYNet income, FY2021: −3.74B CNYNet income, FY2022: −1.37B CNYNet income, FY2023: −255.77M CNYNet income, FY2024: −323.74M CNYNet income, FY2025: −121.05M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.47B CNY. Revenue FY2022 4.12B CNY. Revenue FY2023 4.71B CNY. Revenue FY2024 4.57B CNY. Revenue FY2025 2.02B CNY. Operating income FY2021 −746.04M CNY. Operating income FY2022 −633.13M CNY. Operating income FY2023 −283.57M CNY. Operating income FY2024 −279.59M CNY. Operating income FY2025 −101.71M CNY. Net income FY2021 −3.74B CNY. Net income FY2022 −1.37B CNY. Net income FY2023 −255.77M CNY. Net income FY2024 −323.74M CNY. Net income FY2025 −121.05M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue2.02B CNY4.57B CNY4.71B CNY4.12B CNY3.47B CNY
Cost of goods sold1.74B CNY4.18B CNY4.3B CNY3.78B CNY3.19B CNY
Gross profit277.08M CNY386.43M CNY414.7M CNY337.35M CNY281.06M CNY
Research and development9.93M CNY22.26M CNY45.95M CNY62.65M CNY59.21M CNY
Selling, general, and administrative358.34M CNY602.32M CNY640.11M CNY907.86M CNY961.48M CNY
Operating expenses378.79M CNY666.02M CNY696.02M CNY975.98M CNY1.03B CNY
Interest income8.08M CNY15.82M CNY31.34M CNY17.25M CNY10.37M CNY
Interest expense1.39M CNY3.07M CNY3.49M CNY4.04M CNY3.69M CNY
Depreciation and amortization26.19M CNY14.83M CNY16.08M CNY15.39M CNY52.99M CNY
Operating income−101.71M CNY−279.59M CNY−283.57M CNY−633.13M CNY−746.04M CNY
Net income−121.05M CNY−323.74M CNY−255.77M CNY−1.37B CNY−3.74B CNY

Company facts updated Aug 24, 2026.

0314.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

ETFs holding 0314.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Dimensional - Emerging Markets Core Equity 2 ETF logoDimensional - Emerging Markets Core Equity 2 ETFDFEM
Market value
60.65K
Weight
0.00%
AUM
9.49B USD
Expense ratio
0.39%
Price / 1D
$39.93+0.50%
State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
49.87K
Weight
0.01%
AUM
685.65M USD
Expense ratio
0.65%
Price / 1D
$72.22+0.25%
Dimensional World ex U.S. Core Equity 2 ETF logoDimensional World ex U.S. Core Equity 2 ETFDFAX
Market value
18.41K
Weight
0.00%
AUM
12.57B USD
Expense ratio
0.28%
Price / 1D
$38.16+0.82%
State Street SPDR S&P China ETF logoState Street SPDR S&P China ETFGXC
Market value
1.83K
Weight
0.00%
AUM
474.65M USD
Expense ratio
0.59%
Price / 1D
$91.50+0.51%

Continue in GoAI

Research 0314.HK

research.disclaimer